Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 |
| clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01051934 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 49 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00662311 | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery | terminated | Phase 1 / Phase 2 | 5 | University of WashingtonOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | completed | Phase 1 | 87 | Genentech, Inc.INDUSTRY | 2 | Jun 7, 2017 | clinicaltrials |
| NCT02570958 | ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors(ENB-RIGGS) | withdrawn | Phase 1 | 0 | St. Joseph's Healthcare HamiltonOTHER | 0 | Jun 5, 2017 | clinicaltrials |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | terminated | Phase 1 | 71 | GlaxoSmithKlineINDUSTRY | 6 | May 15, 2017 | clinicaltrials |
| NCT00731952 | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | completed | Phase 1 | 21 | University of VirginiaOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00351039 | Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01069757 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 16 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01251796 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 9 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT01005797 | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | completed | Phase 1 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01731587 | Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer(FINGERPRINT) | withdrawn | Phase 1 | 0 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 0 | Feb 28, 2017 | clinicaltrials |
| NCT00444015 | Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01647711 | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | completed | Phase 1 | 35 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
| NCT01026844 | Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 27 | Massachusetts General HospitalOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT00073723 | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 75 | Celgene CorporationINDUSTRY | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00921310 | Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | terminated | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01886573 | Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00876460 | BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00776698 | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00975182 | A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01839955 | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 | 12 | Neelesh Sharma MD PhDOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT02083679 | Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer | terminated | Phase 1 | 15 | EMD SeronoINDUSTRY | 2 | Oct 25, 2016 | clinicaltrials |
| NCT01605916 | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01521325 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | completed | Phase 1 | 6 | MorphotekINDUSTRY | 1 | Sep 30, 2016 | clinicaltrials |
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Nasser Hanna, M.D.OTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT00850785 | Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer(DRibble) | completed | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00702572 | Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 25 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 22, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2017source: clinicaltrials